Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1958 2
1959 1
1963 1
1968 1
1974 1
1985 1
1989 1
1990 4
1991 2
1992 2
1993 4
1994 2
1995 2
1996 5
1997 2
1998 2
1999 3
2000 11
2001 13
2002 8
2003 10
2004 6
2005 7
2006 8
2007 2
2008 8
2009 8
2010 6
2011 3
2012 7
2013 6
2014 3
2015 5
2016 5
2017 2
2018 5
2019 2
2020 2
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

153 results
Results by year
Filters applied: . Clear all
Page 1
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group. Moskowitz CH, et al. Among authors: sievers el. Lancet. 2015 May 9;385(9980):1853-62. doi: 10.1016/S0140-6736(15)60165-9. Epub 2015 Mar 19. Lancet. 2015. PMID: 25796459 Clinical Trial.
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R. Younes A, et al. Among authors: sievers el. J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26. J Clin Oncol. 2012. PMID: 22454421 Free PMC article. Clinical Trial.
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Younes A, et al. Among authors: sievers el. N Engl J Med. 2010 Nov 4;363(19):1812-21. doi: 10.1056/NEJMoa1002965. N Engl J Med. 2010. PMID: 21047225 Free article. Clinical Trial.
TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
Petrova PS, Viller NN, Wong M, Pang X, Lin GH, Dodge K, Chai V, Chen H, Lee V, House V, Vigo NT, Jin D, Mutukura T, Charbonneau M, Truong T, Viau S, Johnson LD, Linderoth E, Sievers EL, Maleki Vareki S, Figueredo R, Pampillo M, Koropatnick J, Trudel S, Mbong N, Jin L, Wang JC, Uger RA. Petrova PS, et al. Among authors: sievers el. Clin Cancer Res. 2017 Feb 15;23(4):1068-1079. doi: 10.1158/1078-0432.CCR-16-1700. Epub 2016 Nov 17. Clin Cancer Res. 2017. PMID: 27856600 Free article.
Cause and burn.
Rose D, Sievers E, Nichols S. Rose D, et al. Among authors: sievers e. Cognition. 2021 Feb;207:104517. doi: 10.1016/j.cognition.2020.104517. Epub 2020 Dec 9. Cognition. 2021. PMID: 33309004 No abstract available.
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.
Ansell SM, Maris MB, Lesokhin AM, Chen RW, Flinn IW, Sawas A, Minden MD, Villa D, Percival MM, Advani AS, Foran JM, Horwitz SM, Mei MG, Zain J, Savage KJ, Querfeld C, Akilov OE, Johnson LDS, Catalano T, Petrova PS, Uger RA, Sievers EL, Milea A, Roberge K, Shou Y, O'Connor OA. Ansell SM, et al. Among authors: sievers el. Clin Cancer Res. 2021 Apr 15;27(8):2190-2199. doi: 10.1158/1078-0432.CCR-20-3706. Epub 2021 Jan 15. Clin Cancer Res. 2021. PMID: 33451977 Free article.
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A. Pro B, et al. Among authors: sievers el. J Clin Oncol. 2012 Jun 20;30(18):2190-6. doi: 10.1200/JCO.2011.38.0402. Epub 2012 May 21. J Clin Oncol. 2012. PMID: 22614995 Clinical Trial.
[Breastfeeding and potential sensory imprinting].
Kersting M, Sievers E. Kersting M, et al. Among authors: sievers e. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018 Aug;61(8):971-976. doi: 10.1007/s00103-018-2763-6. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018. PMID: 29947853 Review. German.
Non-malignant neutropenia.
Sievers EL, Dale DC. Sievers EL, et al. Blood Rev. 1996 Jun;10(2):95-100. doi: 10.1016/s0268-960x(96)90038-7. Blood Rev. 1996. PMID: 8813341 Review.
153 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page